These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 79114)

  • 1. Naloxone effects on manic symptoms and growth-hormone levels.
    Janowsky D; Judd L; Huey L; Roitman N; Parker D; Segal D
    Lancet; 1978 Aug; 2(8084):320. PubMed ID: 79114
    [No Abstract]   [Full Text] [Related]  

  • 2. Naloxone-induced behavioral and physiological effects in normal and manic subjects.
    Judd LL; Janowsky DS; Segal DS; Huey LY
    Arch Gen Psychiatry; 1980 May; 37(5):583-6. PubMed ID: 7377916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral effects of opioid receptor antagonists in psychopathologic states.
    Janowsky DS; Judd LL; Huey LY; Risch SC; Segal DS
    Psychiatr Clin North Am; 1983 Sep; 6(3):403-14. PubMed ID: 6316300
    [No Abstract]   [Full Text] [Related]  

  • 4. A study of naloxone with schizophrenic and manic patients.
    Sethi BB; Prakash R
    Br J Psychiatry; 1981 Jun; 138():501-3. PubMed ID: 7028200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of naloxone in schizophrenic psychoses and manic syndromes.
    Verhoeven WM; van Praag HM; de Jong JT
    Neuropsychobiology; 1981; 7(3):159-68. PubMed ID: 7231653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Administration of naloxone in schizophrenic psychoses and manic syndromes].
    Verhoeven WM; van Praag HM; de Jong JT
    Ned Tijdschr Geneeskd; 1981 Apr; 125(14):532-7. PubMed ID: 6112715
    [No Abstract]   [Full Text] [Related]  

  • 9. Action of naloxone and naltrexone in different types of psychoses.
    Volavka J
    Mod Probl Pharmacopsychiatry; 1981; 17():202-12. PubMed ID: 6276726
    [No Abstract]   [Full Text] [Related]  

  • 10. Failure of naloxone to reduce manic symptoms.
    Davis GC; Extein I; Reus VI; Hamilton W; Post RM; Goodwin FK; Bunney WE
    Am J Psychiatry; 1980 Dec; 137(12):1583-5. PubMed ID: 7435717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Endorphin studies in psychiatric patients.
    Gorelick DA; Catlin DH; Gerner RH
    Mod Probl Pharmacopsychiatry; 1981; 17():236-45. PubMed ID: 6276728
    [No Abstract]   [Full Text] [Related]  

  • 12. High dose naloxone in depression.
    Cohen MR; Cohen RM; Pickar D; Sunderland T; Mueller EA; Murphy DL
    Biol Psychiatry; 1984 Jun; 19(6):825-32. PubMed ID: 6743720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
    Scheffer RE; Kowatch RA; Carmody T; Rush AJ
    Am J Psychiatry; 2005 Jan; 162(1):58-64. PubMed ID: 15625202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention and distribution patterns of lithium, a pharmacological tool in studying the pathophysiology of manic-depressive psychosis.
    Greenspan K; Green R; Durell J
    Am J Psychiatry; 1968 Oct; 125(4):512-9. PubMed ID: 4886105
    [No Abstract]   [Full Text] [Related]  

  • 15. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.
    Lehmann H; Nair NP; Kline NS
    Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of naloxone on the state of patients with endogenous psychoses.
    Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
    Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
    [No Abstract]   [Full Text] [Related]  

  • 17. Carbamazepine versus lithium in mania: a double-blind study.
    Lerer B; Moore N; Meyendorff E; Cho SR; Gershon S
    J Clin Psychiatry; 1987 Mar; 48(3):89-93. PubMed ID: 3546274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of carbamazepine in affective illness: a preliminary report.
    Ballenger JC; Post RM
    Commun Psychopharmacol; 1978; 2(2):159-75. PubMed ID: 352607
    [No Abstract]   [Full Text] [Related]  

  • 19. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant effects of carbamazepine.
    Post RM; Uhde TW; Roy-Byrne PP; Joffe RT
    Am J Psychiatry; 1986 Jan; 143(1):29-34. PubMed ID: 3510572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.